APT070 (mirococept), a membrane-localizing C3 convertase inhibitor, attenuates early human islet allograft damage in vitro and in vivo in a humanized mouse model

British Journal of Pharmacology

Volumn 173, Issue 3, 2016, Pages 575-587

  Xiao, Fang ^a   Ma, Liang ^a   Zhao, Min ^b   Smith, Richard A ^a   Huang, Guocai ^b   Jones, Peter M ^a   Persaud, Shanta ^a   Pingitore, Attilio ^a   Dorling, Anthony ^a   Lechler, Robert ^a   Lombardi, Giovanna ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APT 154; C PEPTIDE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LACTATE DEHYDROGENASE; LYMPHOTOXIN; MIROCOCEPT; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; CYTOKINE; IL2RG PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR GAMMA;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CELL INFILTRATION; CELL VIABILITY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME RELEASE; GRAFT REJECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; INSULIN RELEASE; MOUSE; NONHUMAN; PANCREAS ISLET CELL; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CELL CULTURE; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; NONOBESE DIABETIC MOUSE; PANCREAS ISLET; PANCREAS ISLET TRANSPLANTATION; SCID MOUSE; XENOGRAFT;

ANIMALS; CELLS, CULTURED; COMPLEMENT C3-C5 CONVERTASES; CYTOKINES; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; TRANSPLANTATION, HETEROLOGOUS;

EID: 84956747250     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13388     Document Type: Article

References (62)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
2. Banz Y, Hess OM, Robson SC, Csizmadia E, Mettler D, Meier P, et al., (2007). Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1. Cardiovasc Res 76: 482-493.
3. Bennet W, Groth CG, Larsson R, Nilsson B, Korsgren O, (2000a). Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci 105: 125-133.
4. Bennet W, Sundberg B, Lundgren T, Tibell A, Groth CG, Richards A, et al., (2000b). Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomologus monkeys: protective effects of sCR1 and heparin. Transplantation 69: 711-719.
5. Brehm MA, Cuthbert A, Yang C, Miller DM, DiIorio P, Laning J, et al. (2010a). Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin Immunol 135: 84-98.
6. Brehm MA, Shultz LD, Greiner DL, (2010b) Humanized mouse models to study human diseases. Curr Opin Endocrinol Diabetes Obes 17: 120-125.
7. Brehm MA, Shultz LD, Luban J, Greiner DL, (2013). Overcoming current limitations in humanized mouse research. J Infect Dis 208 (Suppl 2): S125-S130.
8. Brown KM, Kondeatis E, Vaughan RW, Kon SP, Farmer CK, Taylor JD, et al., (2006). Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med 354: 2014-2023.
9. Cao X, Shores EW, Hu-Li J, Anver MR, Kelsall BL, Russell SM, et al., (1995). Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 2: 223-238.
10. Chen H, Teramura Y, Iwata H, (2011). Co-immobilization of urokinase and thrombomodulin on islet surfaces by poly(ethylene glycol)-conjugated phospholipid. Journal of controlled release: official journal of the Controlled Release Society 150: 229-234.
11. Choi SE, Choi KM, Yoon IH, Shin JY, Kim JS, Park WY, et al., (2004). IL-6 protects pancreatic islet beta cells from pro-inflammatory cytokines-induced cell death and functional impairment in vitro and in vivo. Transpl Immunol 13: 43-53.
12. Citro A, Cantarelli E, Piemonti L, (2013). Anti-inflammatory strategies to enhance islet engraftment and survival. Curr Diab Rep 13: 733-744.
13. Covassin L, Laning J, Abdi R, Langevin DL, Phillips NE, Shultz LD, et al., (2011). Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rgamma(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease. Clin Exp Immunol 166: 269-280.
14. Curtis, M. J., Bond, R. A., Spina, D., Ahluwalia, A., Alexander, S. P. A., Giembycz, M. A et al., (2015), Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461-3471.
15. de Silva RJ, Vuylsteke A, Fritchley SJ, Trull AK, Dunning JJ, Wallwork J, (2006). APT070 inhibits complement activation during in vitro cardiopulmonary bypass. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery 30: 72-76.
16. DiSanto JP, Muller W, Guy-Grand D, Fischer A, Rajewsky K, (1995). Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc Natl Acad Sci U S A 92: 377-381.
17. Dodd I, Mossakowska DE, Camilleri P, Haran M, Hensley P, Lawlor EJ, et al., (1995). Overexpression in Escherichia coli, folding, purification, and characterization of the first three short consensus repeat modules of human complement receptor type 1. Protein Expr Purif 6: 727-736.
18. Farrar CA, Sacks SH, (2014). Mechanisms of rejection: role of complement. Curr Opin Organ Transplant 19: 8-13.
19. Halstead SK, Humphreys PD, Goodfellow JA, Wagner ER, Smith RA, Willison HJ, (2005). Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann Neurol 58: 203-210.
20. Hansen WA, Christie MR, Kahn R, Norgaard A, Abel I, Petersen AM, et al., (1989). Supravital dithizone staining in the isolation of human and rat pancreatic islets. Diabetes Res 10: 53-57.
21. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, et al., (2005). Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 106: 1565-1573.
22. Johansson U, Olsson A, Gabrielsson S, Nilsson B, Korsgren O, (2003). Inflammatory mediators expressed in human islets of Langerhans: implications for islet transplantation. Biochem Biophys Res Commun 308: 474-479.
23. Jones PM, Persaud SJ, Howell SL, (1989). Time-course of Ca2 + -induced insulin secretion from perifused, electrically permeabilised islets of Langerhans: effects of cAMP and a phorbol ester. Biochem Biophys Res Commun 162: 998-1003.
24. Jones PM, Salmon DM, Howell SL, (1988). Protein phosphorylation in electrically permeabilized islets of Langerhans. Effects of Ca2+, cyclic AMP, a phorbol ester and noradrenaline. Biochem J 254: 397-403.
25. King M, Pearson T, Shultz LD, Leif J, Bottino R, Trucco M, et al., (2008). A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin Immunol 126: 303-314.
26. Li K, Zhou W, (2013). Anaphylatoxins in organ transplantation. Semin Immunol 25: 20-28.
27. London NJ, Contractor H, Lake SP, Aucott GC, Bell PR, James RF, (1989). A microfluorometric viability assay for isolated human and rat islets of Langerhans. Diabetes Res 12: 141-149.
28. Luan NM, Teramura Y, Iwata H, (2011). Immobilization of soluble complement receptor 1 on islets. Biomaterials 32: 4539-4545.
29. Lundgren T, Bennet W, Tibell A, Soderlund J, Sundberg B, Song Z, et al., (2001). Soluble complement receptor 1 (TP10) preserves adult porcine islet morphology after intraportal transplantation into cynomolgus monkeys. Transplant Proc 33 (1-2): 725.
30. McGrath JC, Lilley E, (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189-3193.
31. McGrath JC, McLachlan EM, Zeller R, (2015). Transparency in Research involving Animals: The Basel Declaration and new principles for reporting research in BJP manuscripts. Br J Pharmacol 172: 2427-2432.
32. Moberg L, Johansson H, Lukinius A, Berne C, Foss A, Kallen R, et al., (2002). Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 360: 2039-2045.
33. Moberg L, Korsgren O, Nilsson B, (2005). Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible blood. Clin Exp Immunol 142: 125-131.
34. Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G, et al., (2002). Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100: 1869-1877.
35. Mossakowska D, Dodd I, Pindar W, Smith RA, (1999). Structure-activity relationships within the N-terminal short consensus repeats (SCR) of human CR1 (C3b/C4b receptor, CD35): SCR 3 plays a critical role in inhibition of the classical and alternative pathways of complement activation. Eur J Immunol 29: 1955-1965.
36. Nilsson B, Ekdahl KN, Korsgren O, (2011). Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment. Curr Opin Organ Transplant 16: 620-626.
37. Ohbo K, Suda T, Hashiyama M, Mantani A, Ikebe M, Miyakawa K, et al., (1996). Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood 87: 956-967.
38. Patel H, Smith RA, Sacks SH, Zhou W, (2006). Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. Journal of the American Society of Nephrology: JASN 17: 1102-1111.
39. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ,; NC-IUPHAR. (2014) The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-1106.
40. Peng Q, Li K, Anderson K, Farrar CA, Lu B, Smith RA, et al., (2008). Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction. Blood 111: 2452-2461.
41. Robertson RP, (2010). Islet transplantation a decade later and strategies for filling a half-full glass. Diabetes 59: 1285-1291.
42. Sacks S, Lee Q, Wong W, Zhou W, (2009). The role of complement in regulating the alloresponse. Curr Opin Organ Transplant 14: 10-15.
43. Serra-Hassoun M, Bourgine M, Boniotto M, Berges J, Langa F, Michel ML, et al., (2014). Human hematopoietic reconstitution and HLA-restricted responses in nonpermissive alymphoid mice. J Immunol 193: 1504-1511.
44. Shultz LD, Ishikawa F, Greiner DL, (2007). Humanized mice in translational biomedical research. Nature reviews. Immunology 7: 118-130.
45. Shultz LD, Saito Y, Najima Y, Tanaka S, Ochi T, Tomizawa M, et al., (2010). Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice. Proc Natl Acad Sci U S A 107: 13022-13027.
46. Smith GP, Smith RA, (2001). Membrane-targeted complement inhibitors. Mol Immunol 38 (2-3): 249-255.
47. Smith RA, (2002). Targeting anticomplement agents. Biochem Soc Trans 30 (Pt 6): 1037-1041.
48. Smith RAGKG, Chowdhury P, Smith KKC, Watson CJ, Nicholson ML, Zhou WD, et al., (2007). Membrane-localising complement inhibitors-clinical progress. Mol Immunol 44: 1.
49. Souza DG, Esser D, Bradford R, Vieira AT, Teixeira MM, (2005). APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br J Pharmacol 145: 1027-1034.
50. Souza DG, Guabiraba R, Pinho V, Bristow A, Poole S, Teixeira MM, (2003). IL-1-driven endogenous IL-10 production protects against the systemic and local acute inflammatory response following intestinal reperfusion injury. J Immunol 170: 4759-4766.
51. Teramura Y, Iwata H, (2011). Improvement of graft survival by surface modification with poly(ethylene glycol)-lipid and urokinase in intraportal islet transplantation. Transplantation 91: 271-278.
52. Tjernberg J, Ekdahl KN, Lambris JD, Korsgren O, Nilsson B, (2008). Acute antibody-mediated complement activation mediates lysis of pancreatic islets cells and may cause tissue loss in clinical islet transplantation. Transplantation 85: 1193-1199.
53. Tokodai K, Goto M, Inagaki A, Nakanishi W, Ogawa N, Satoh K, et al., (2010). Attenuation of cross-talk between the complement and coagulation cascades by C5a blockade improves early outcomes after intraportal islet transplantation. Transplantation 90: 1358-1365.
54. Torrealba JR, Samaniego M, Pascual J, Becker Y, Pirsch J, Sollinger H, et al., (2008). C4d-positive interacinar capillaries correlates with donor-specific antibody-mediated rejection in pancreas allografts. Transplantation 86: 1849-1856.
55. van der Windt DJ, Bottino R, Casu A, Campanile N, Cooper DK, (2007). Rapid loss of intraportally transplanted islets: an overview of pathophysiology and preventive strategies. Xenotransplantation 14: 288-297.
56. van der Windt DJ, Marigliano M, He J, Votyakova TV, Echeverri GJ, Ekser B, et al., (2012). Early islet damage after direct exposure of pig islets to blood: has humoral immunity been underestimated? Cell Transplant 21: 1791-1802.
57. Walport MJ, (2001a). Complement. First of two parts. N Engl J Med 344: 1058-1066.
58. Walport MJ, (2001b). Complement. Second of two parts. N Engl J Med 344: 1140-1144.
59. Watanabe Y, Takahashi T, Okajima A, Shiokawa M, Ishii N, Katano I, et al., (2009). The analysis of the functions of human B and T cells in humanized NOD/shi-scid/gammac(null) (NOG) mice (hu-HSC NOG mice). Int Immunol 21: 843-858.
60. Xiao F, Ma L, Zhao M, Huang G, Mirenda V, Dorling A, et al., (2014). Ex vivo expanded human regulatory T cells delay islet allograft rejection via inhibiting islet-derived monocyte chemoattractant protein-1 production in CD34+ stem cells-reconstituted NOD-scid IL2rgammanull mice. PLoS One 9: e90387.
61. Yi S, Ji M, Wu J, Ma X, Phillips P, Hawthorne WJ, et al., (2012). Adoptive transfer with in vitro expanded human regulatory T cells protects against porcine islet xenograft rejection via interleukin-10 in humanized mice. Diabetes 61: 1180-1191.
62. Zhou W, Patel H, Li K, Peng Q, Villiers MB, Sacks SH, (2006). Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells. Blood 107: 2461-2469.